Exact Mass: 583.1811
Exact Mass Matches: 583.1811
Found 106 metabolites which its exact mass value is equals to given mass value 583.1811
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Fostemsavir
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D065147 - Viral Fusion Protein Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D065147 - Viral Fusion Protein Inhibitors > D023581 - HIV Fusion Inhibitors
N-succinyl-chitosan
Cys Glu Phe Trp
Cys Glu Trp Phe
Cys Phe Glu Trp
Cys Phe Trp Glu
Cys Trp Glu Phe
Cys Trp Phe Glu
Asp Thr Trp Tyr
Asp Thr Tyr Trp
Asp Trp Thr Tyr
Asp Trp Tyr Thr
Asp Tyr Thr Trp
Asp Tyr Trp Thr
Glu Cys Phe Trp
Glu Cys Trp Phe
Glu Phe Cys Trp
Glu Phe Trp Cys
Glu Ser Trp Tyr
Glu Ser Tyr Trp
Glu Trp Cys Phe
Glu Trp Phe Cys
Glu Trp Ser Tyr
Glu Trp Tyr Ser
Glu Tyr Ser Trp
Glu Tyr Trp Ser
Phe Cys Glu Trp
Phe Cys Trp Glu
Phe Glu Cys Trp
Phe Glu Trp Cys
Phe Trp Cys Glu
Phe Trp Glu Cys
Ser Glu Trp Tyr
Ser Glu Tyr Trp
Ser Trp Glu Tyr
Ser Trp Tyr Glu
Ser Tyr Glu Trp
Ser Tyr Trp Glu
Thr Asp Trp Tyr
Thr Asp Tyr Trp
Thr Trp Asp Tyr
Thr Trp Tyr Asp
Thr Tyr Asp Trp
Thr Tyr Trp Asp
Trp Cys Glu Phe
Trp Cys Phe Glu
Trp Asp Thr Tyr
Trp Asp Tyr Thr
Trp Glu Cys Phe
Trp Glu Phe Cys
Trp Glu Ser Tyr
Trp Glu Tyr Ser
Trp Phe Cys Glu
Trp Phe Glu Cys
Trp Ser Glu Tyr
Trp Ser Tyr Glu
Trp Thr Asp Tyr
Trp Thr Tyr Asp
Trp Tyr Asp Thr
Trp Tyr Glu Ser
Trp Tyr Ser Glu
Trp Tyr Thr Asp
Tyr Asp Thr Trp
Tyr Asp Trp Thr
Tyr Glu Ser Trp
Tyr Glu Trp Ser
Tyr Ser Glu Trp
Tyr Ser Trp Glu
Tyr Thr Asp Trp
Tyr Thr Trp Asp
Tyr Trp Asp Thr
Tyr Trp Glu Ser
Tyr Trp Ser Glu
Tyr Trp Thr Asp
(3R,4S)-tert-Butyl 3-(bis(4-Methoxyphenyl)(phenyl)Methoxy)-4-((Methylsulfonyl)oxy)pyrrolidine-1-carboxylate
Nilotinib hydrochloride monohydrate
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor
methyl (phenyl 5-acetamido-4,7,8,9-tetra-o-acetyl-3,5-dideoxy-2-thio-d-glycero-d-galacto-2-nonulopyranosid)onate
4-[6-[(6-Bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7- oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1- piperazinecarboxylic acid 1,1-dimethylethyl ester
Methyl 2-[(2-methylpyridin-4-yl)methyl]-1-oxo-8-(pyrimidin-2-ylmethoxy)-4-(3,4,5-trimethoxyphenyl)-1,2-dihydro-2,7-naphthyridine-3-carboxylate
Fostemsavir
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D065147 - Viral Fusion Protein Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D065147 - Viral Fusion Protein Inhibitors > D023581 - HIV Fusion Inhibitors
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-gammaGlu-L-gammaGlu-OH
1-[5-[3-Amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[5-amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-3-yl]pyrrolidine-2,5-dione
N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(2-pyridin-4-ylethynyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N,4-dimethylbenzenesulfonamide
ASTX029
ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor (IC50: 2.7 nM). ASTX029 has anti-cancer activity[1][2].
AZD-8529 (mesylate)
AZD-8529 mesylate is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes[1].